Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site
Zhiqing Liu, Yi Li, Haiying Chen, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 2388-2408
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Bromodomain inhibitors and therapeutic applications
G. Bharath Kumar, Ming‐Ming Zhou
Current Opinion in Chemical Biology (2023) Vol. 75, pp. 102323-102323
Open Access | Times Cited: 30
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia
Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1513-1532
Closed Access | Times Cited: 10
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Juncheng Chen, Pan Tang, Yuxi Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5184-5211
Closed Access | Times Cited: 36
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective
Haixiang Pei, Weikai Guo, Yangrui Peng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 4, pp. 1607-1660
Closed Access | Times Cited: 31
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Zonghui Ma, Andrew A. Bolinger, Haiying Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10991-11026
Open Access | Times Cited: 20
Recent progress and structural analyses of domain‐selective BET inhibitors
Anand Divakaran, Daniel A. Harki, William C. K. Pomerantz
Medicinal Research Reviews (2023) Vol. 43, Iss. 4, pp. 972-1018
Open Access | Times Cited: 18
Targeting bromodomain-containing proteins: research advances of drug discovery
Zhaoping Pan, Yuxi Zhao, Xiaoyun Wang, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 18
An updated patent review of BRD4 degraders
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics
Zonghui Ma, Andrew A. Bolinger, Jia Zhou, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 1, pp. 1-7
Open Access | Times Cited: 16
Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors
Yangfeng Li, Zhengnan Shen, Kiira Ratia, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2712-2731
Closed Access | Times Cited: 5
Multi-Water Bridges Enable Design of BET BD1-Selective Inhibitors for Pancreatic Cancer Therapy
Xuetao Chen, Wenjing Kang, Tingting Wu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease
Zonghui Ma, Steven McAninch, Zhiqing Liu, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 4, pp. 1152-1167
Closed Access
Efficacy and Toxicity Analysis of Selective BET Bromodomain Inhibitors in Models of Inflammatory Liver Disease
Luke C. Doskey, Cole R. Scholtz, Nora R. Vail, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors
Shwu‐Yuan Wu, Hsien‐Tsung Lai, N. Sanjib Banerjee, et al.
Molecular Cell (2023) Vol. 84, Iss. 2, pp. 202-220.e15
Closed Access | Times Cited: 9
Cooperative interaction of interferon regulatory factor -1 and bromodomain—containing protein 4 on RNA polymerase activation for intrinsic innate immunity
Xiaofang Xu, Dianhua Qiao, Allan R. Brasier
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
BRD4: an effective target for organ fibrosis
Qun Wei, Cailing Gan, Meng Sun, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors
Junhua Li, Qingqing Hu, Run Zhu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors
Junhua Li, Cheng Zhang, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5760-5799
Closed Access | Times Cited: 15
Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis
Xuetao Chen, Tingting Wu, Zhiyan Du, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116080-116080
Closed Access | Times Cited: 7
Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling
Bin Wang, Jian Wang, Wanchun Yang, et al.
Molecules (2024) Vol. 29, Iss. 15, pp. 3496-3496
Open Access | Times Cited: 2
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432
P. G. Humphreys, Niall A. Anderson, Paul Bamborough, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15174-15207
Open Access | Times Cited: 12
Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis
Ksenija Bernau, Melissa Skibba, Jonathan P. Leet, et al.
Frontiers in Molecular Medicine (2022) Vol. 2
Open Access | Times Cited: 11
Targeting lysine acetylation readers and writers
Ming‐Ming Zhou, Philip A. Cole
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 2
Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer
Yonglei Zhang, Long Zheng, Liangliang Ma, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 23, pp. 21186-21207
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top